Breaking News

Single-Shot Chikungunya Vaccine Candidate Confirms Positive Antibody Persistence

December 5, 2022 • 6:54 am CST
U.S. CDC
(Precision Vaccinations News)

Valneva SE today reported positive antibody persistence data twelve months after vaccination with a single dose of its chikungunya vaccine candidate, VLA1553.

Furthermore, antibody levels remained stable between month 6 to month 12, and there were no safety concerns identified during follow-up, confirming VLA1553's safety profile observed in earlier studies.

This finding is essential since the U.S. FDA has not approved any chikungunya vaccine candidate as of December 5, 2022.

Chikungunya is a mosquito-borne viral disease that often causes sudden large outbreaks with high attack rates, affecting about one-third of the population in areas where the virus is circulating, says the U.S. CDC.

Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva, commented in a press release on December 5, 2022, "We are excited about these twelve-month data which are in line with what we saw from our previous read out at month six, and strengthen the possibilities of inducing a long-lasting antibody response with our chikungunya vaccine candidate."

"We look forward to completing the BLA rolling submission to the FDA and potentially changing people's lives."

"If our investigational vaccine is approved, we are confident it can help address this growing public health threat."

Valneva expects to finalize its BLA submission with the FDA by the end of 2022.

Once completed, and if the FDA accepts the filing, the FDA will determine priority review eligibility along with the action due date upon which it will complete its evaluation.

Valneva also initiated a Phase 3 trial in adolescents conducted in Brazil by Instituto Butantan to support the label extension in this age group following a potential initial regulatory approval.

Additional chikungunya vaccine candidate news is posted at PrecisionVaccinations.com/Chilungunya.

Our Trust Standards: Medical Advisory Committee

Share